Microplate Dx
Glasgow, GB · Founded 2021 · Incorporated in United Kingdom · 5 known investors
Find your way into Microplate Dx
133 people in our graph share verified history with the Microplate Dx team — schools, employers, funds. One of them is your warm intro.
Rowena Patelunlockedknows Dr Stuart Hannah · together at University of Strathclyde (overlapped)
×11knows the team · via University of Strathclyde
Microplate Dx is a diagnostics company developing rapid antimicrobial susceptibility testing technology to identify the correct antibiotic treatment for infections within hours, enabling faster patient treatment and reducing antibiotic resistance. The company targets healthcare providers and focuses on improving clinical outcomes in infectious disease management.
Founders & leadership
Microplate Dx was founded in 2021 by Dr Stuart Hannah.
DS
Dr Stuart HannahinCo-Founder & CEODr. Stuart Hannah is co-founder and CEO of Microplate Dx, a diagnostics company developing rapid antimicrobial susceptibility testing technology to identify appropriate antibiotic treatments for infections.
Board
PM
Poonam MalikBoard director
AJ
Andrew Justin Radcliffe PorterBoard director
Investors · 5
Also in the syndicate · 3
SIS VenturesThairm BioUniversity of Strathclyde
Funding
SEC filings, press & company announcements$2.1M disclosed across 2 of 3 rounds · 2022–2025
- Undisclosed amountseed fundingDec 2022Source ↗
▶$644.6KraisedSep 2025 · 3 investors · Other TechnologyRule 506(b)
▶$644.6KraisedSep 2025 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew Justin Radcliffe PorterDirector
- Stuart Matthew HannahExecutive Officer, Director
- Poonam MalikExecutive Officer, Director
- Amount sold
- $644.6K
- First sale
- Sep 2025
- Incorporated
- Other, United Kingdom, 2021
- Federal exemptions
- 06b
▶$1.4MraisedJul 2023 · 6 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJul 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MBM SECRETARIAL SERVICES LIMITEDExecutive Officer
- Poonam MalikDirector
- Andrew Justin Radcliffe PorterDirector
- Stuart Matthew HannahDirector
- Amount sold
- $1.4M
- First sale
- Jul 2023
- Incorporated
- Other, United Kingdom, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Revvity6 shared keywordsRevvity develops and sells reagents, instruments, software, and services for life sciences research and clinical diagnostics, serving pharmaceutical, biotech, academic and government institutions across drug discovery, development, and disease diagnosis workflows.
Agilent5 shared keywordsAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).
Companies competing with Microplate Dx for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- MICROPLATE DX LIMITED
- Company number
- SC706330
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Aug 2021
- Registered office
- Suite 534 Royal College Building, 204 George Street, Glasgow, G1 1XW
- Nature of business (SIC)
- 74909 — Other professional, scientific and technical activities n.e.c.
- Accounts
- last made up to 30 Apr 2025 · next due 31 Jan 2027
- Confirmation statement
- last made up to 9 Aug 2025 · next due 23 Aug 2026
Current officers · 6
- Mbm Secretarial Services Limited — corporate secretary, appointed 29 Mar 2023
- Nicola Broughton — director, appointed 1 Jul 2026
- Stuart Matthew Hannah — director, appointed 10 Aug 2021
- Poonam Malik — director, appointed 10 Aug 2021
- Andrew Justin Radcliffe Porter — director, appointed 7 Mar 2022
- Michael Rasche — director, appointed 18 Apr 2026
Source: Companies House public register · retrieved 6 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Microplate Dx do?
- Microplate Dx is a diagnostics company developing rapid antimicrobial susceptibility testing technology to identify the correct antibiotic treatment for infections within hours, enabling faster patient treatment and reducing antibiotic resistance. The company targets healthcare providers and focuses on improving clinical outcomes in infectious disease management.
- Who founded Microplate Dx?
- Microplate Dx was founded by Dr Stuart Hannah in 2021.
- Who are Microplate Dx's investors?
- Microplate Dx's investors include Deepbridge Capital, Scottish Enterprise.
- How much funding has Microplate Dx raised?
- Microplate Dx has disclosed $2.1M raised across 2 of its 3 known rounds.
- Where is Microplate Dx headquartered?
- Microplate Dx is headquartered in Glasgow, GB.